Serving emerging markets generally requires local production--and that means investments in upgrades. That is the phase Eli Lilly is in with a packaging operation in São Paulo, Brazil.
With some of its larger rivals already at work on biotech knockoffs, Indian drugmaker Lupin is on the hunt for partners to help shepherd it into the biosimilar fray, taking aim at top-selling treatments soon to come off patent.
Bayer already has a big footprint in China, where it's been selling drugs since the 1930s. But that footprint is about to get a bit bigger. The company is set to buy out China's Dihon Pharmaceutical Group, a company that specializes in OTC drugs--making it just the kind of pickup the German drugmaker's been scouting for.
The FDA has taken some tough action against Indian drugmakers like Ranbaxy Laboratories. It has a dozen inspectors stationed in India and will beef that up to 19. But the agency doesn't have it out for Indian drugmakers, FDA Commissioner Margaret Hamburg insists. Its actions there just reflects that India has become one of the biggest links in the global supply chain.
China has yet to leverage any formal penalties on GlaxoSmithKline for the $489 million bribery scandal that broke there last summer. But punishment may be on the way from GSK's home base.
GE Healthcare is readying space in Helsinki to host new startups, according to a report--a strategic way to tap into new technology as it continues to expand globally.
Merck KGaA went through a serious downsizing after its key multiple sclerosis drug candidate failed two years ago. But having rebounded faster than it expected, the German drugmaker is making some serious noise about being a more significant force.
Getting costs down on vaccines is always a big deal to countries like India, and so the government there is putting pressure on GlaxoSmithKline and Merck to give it a break on the human papillomavirus (HPV) vaccines, according to The New Indian Express.
Emerging markets have become more important for pharma, and that is no different for the companies that supply drugmakers. West Pharmaceutical Services, which makes packaging and delivery systems for sterile drug manufacturing, said international sales were a growth driver last year.
France's Acerde, which develops parts for X-ray tubes used in medical imaging, said it inked a development contract with an unnamed "China-based player " in the medical imaging space.